Recent Finacing
Recent Raise
Adrenomed AG is a clinical-stage biopharmaceutical company developing Adrecizumab, a monoclonal antibody targeting adrenomedullin to restore vascular integrity in septic shock via biomarker-guided clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Adrenomed.
